The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Muscarinic acetylcholine receptors as CNS drug targets
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225
Koob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Levey, A., Kitt, C., Simonds, W., Price, D., & Brann, M. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-10-03218.1991 · Cited by 918
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Mash, D. C., Flynn, D. D., & Potter, L. T. (1985) · Science · doi:10.1126/science.3992249 · Cited by 698
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas-Kramarski, R., Jaffe, E. A., Gandy, S. E., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10075 · Cited by 559
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003) · Nature Neuroscience · doi:10.1038/nn992 · Cited by 544
From dopamine to salience to psychosis—Linking biology, pharmacology and phenomenology of psychosis
Kapur, S., Mizrahi, R., & Li, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.003 · Cited by 512
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.
Weiner, D. M., Levey, A. I., & Brann, M. R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7050 · Cited by 480
van Kesteren, R. E., Syed, N. I., Munno, D. W., Bouwman, J., Feng, Z.-P., Geraerts, W. P. M., & Smit, A. B. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-j0004.2001 · Cited by 470
Levey, A., Edmunds, S., Koliatsos, V, Wiley, R., & Heilman, C. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04077.1995 · Cited by 422
M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice
Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications
Wess, J. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121622 · Cited by 380
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease
Kar, S., Slowikowski, S. P. M., Westaway, D., & Mount, H. T. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0442 · Cited by 364
Acetylcholine, Aging, and Alzheimer's Disease
Muir, J. L. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00431-5 · Cited by 360
Cognitive deficits as treatment targets in schizophrenia
Gold, J. M. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.008 · Cited by 354
Cholinergic-Anticholinergic Antagonism in Parkinsonism
Duvoisin, R. C. (1967) · Archives of Neurology · doi:10.1001/archneur.1967.00470260014002 · Cited by 342
Animal models of Alzheimer's disease: experimental cholinergic denervation
Smith, G. (1988) · Brain Research Reviews · doi:10.1016/0165-0173(88)90016-1 · Cited by 337
Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C.-X., & Wess, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10483 · Cited by 322
Hagan, J. J., Salamone, J. D., Simpson, J., Iversen, S. D., & Morris, R. G. M. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90105-2 · Cited by 290
Vilaró, M. T., Palacios, J., & Mengod, G. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90064-g · Cited by 268
Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G., & Tonegawa, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261583798 · Cited by 264
Anticholinergics for symptomatic management of Parkinson´s disease
Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003735 · Cited by 259
Shinoe, T., Matsui, M., Taketo, M. M., & Manabe, T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2338-05.2005 · Cited by 241
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs
Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J., & Perry, R. H. (2003) · Annals of Neurology · doi:10.1002/ana.10639 · Cited by 231
Futami, T., Takakusaki, K., & Kitai, S. T. (1995) · Neuroscience Research · doi:10.1016/0168-0102(94)00869-h · Cited by 230
Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228
Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
Murphy, B. P., Chung, Y.-C., Park, T.-W., & McGorry, P. D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.002 · Cited by 217
In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia
Raedler, T. J., Knable, M. B., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K. S., Egan, M. F., Coppola, R., & Weinberger, D. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.118 · Cited by 216
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211
Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
Dean, B., McLeod, M., Keriakous, D., McKenzie, J., & Scarr, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001199 · Cited by 207
Basile, A. S., Fedorova, I., Zapata, A., Liu, X., Shippenberg, T., Duttaroy, A., Yamada, M., & Wess, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162371899 · Cited by 195
Discovery of an Ectopic Activation Site on the M1Muscarinic Receptor
Spalding, T. A., Trotter, C., Skjærbæk, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., & Brann, M. R. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12088-3 · Cited by 193
Tzavara, E. T., Bymaster, F. P., Davis, R. J., Wade, M. R., Perry, K. W., Wess, J., McKinzie, D. L., Felder, C., & Nomikos, G. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-1575fje · Cited by 191
Acetylcholinesterase Inhibition in Alzheimers Disease
Ibach, B., & Haen, E. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043386509 · Cited by 190
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Greenwood, B., Mitch, C. H., Sawyer, B. D., Ward, J. S., Wong, D. T., Olesen, P. H., & Sheardown, M. J. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38667-2 · Cited by 186
Friedman, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1794-x · Cited by 184
Ince, E., Ciliax, B. J., & Levey, A. I. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199712)27:4<357::aid-syn9>3.0.co;2-b · Cited by 175
Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists
Mirza, N. R., Peters, D., & Sparks, R. G. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00247.x · Cited by 175
Fisher, A., Pittel, Z., Haring, R., Bar-Ner, N., Kliger-Spatz, M., Natan, N., Egozi, I., Sonego, H., Marcovitch, I., & Brandeis, R. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:349 · Cited by 173
Laruelle, M. A., Frankle, W. G., Narendran, R., Kegeles, L. S., & Abi‐Dargham, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.017 · Cited by 171
Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., Jeppesen, L., Sheardown, M. J., Sauerberg, P., & Fink-Jensen, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00138-3 · Cited by 165
Blaha, C. D., & Winn, P. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-03-01035.1993 · Cited by 158
Forster, G. L., Yeomans, J. S., Takeuchi, J., & Blaha, C. D. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-01-j0001.2002 · Cited by 152
Dean, B., Crook, J. M., Opeskin, K., Hill, C., Keks, N. A., & Copolov, D. (1996) · PubMed · Cited by 149
Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone
Schubert, M., Young, K. A., & Hicks, P. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.006 · Cited by 147
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat
Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29291-0 · Cited by 142
Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease
Fuentealba, R. A., Farías, G. G., Scheu, J., Bronfman, M., Marzolo, M., & Inestrosa, N. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.018 · Cited by 140
Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine
Hagan, J. J., Jansen, J. H. M., & Broekkamp, C. L. E. (1987) · Psychopharmacology · doi:10.1007/bf00207237 · Cited by 136
Psychosis of Alzheimer’s disease is associated with elevated muscarinic M 2 binding in the cortex
Lai, M. K. P., Lai, O. –., Keene, J., Esiri, M. M., Francis, P. T., Hope, T., & Chen, C. (2001) · Neurology · doi:10.1212/wnl.57.5.805 · Cited by 123
Haring, R., Fisher, A., Marciano, D., Pittel, Z., Kloog, Y., Zuckerman, A., Eshhar, N., & Heldman, E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052094.x · Cited by 122
Reduced Cocaine Self-Administration in Muscarinic M5Acetylcholine Receptor-Deficient Mice
Thomsen, M., Woldbye, D. P. D., Wörtwein, G., Fink‐Jensen, A., Wess, J., & Caine, S. B. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2077-05.2005 · Cited by 121
Mesopontine neurons in schizophrenia
García‐Rill, E., Biedermann, J., Chambers, T. C., Skinner, R. D., Mrak, R. E., Husain, M., & Karson, C. N. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00564-l · Cited by 120
Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease
Clader, J. W., & Wang, Y. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774370762 · Cited by 112
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
Bymaster, F. P., Whitesitt, C. A., Shannon, H. E., DeLapp, N. W., Ward, J. S., Calligaro, D. O., Shipley, L. A., Buelke-Sam, J., Bodick, N. C., Farde, L., et al. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199702)40:2<158::aid-ddr6>3.0.co;2-k · Cited by 109
Langmead, C. J., Fry, V. A. H., Forbes, I. T., Branch, C. L., Christopoulos, A., Wood, M. D., & Herdon, H. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.017814 · Cited by 108
Self-citationTsang, S. W. Y., Lai, M. K. P., Kirvell, S. L., Francis, P. T., Esiri, M. M., Hope, T., Chen, C., & Wong, P. T. ‐. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.010 · Cited by 106
Billard, W., Binch, H., Crosby, G., & McQuade, R. D. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09528-x · Cited by 103
Giachetti, A., Giraldo, E., Ladinsky, H., & Montagna, E. (1986) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1986.tb11123.x · Cited by 102
Forlenza, O. V., Spink, J. M., Dayanandan, R., Anderton, B. H., Olesen, O. F., & Lovestone, S. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070034 · Cited by 101
Miller, A. D., & Blaha, C. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04017.x · Cited by 93
Fuller, S. J., Storey, E., Li, Q.-X., Smith, A. I., Beyreuther, K., & Masters, C. L. (1995) · Biochemistry · doi:10.1021/bi00025a015 · Cited by 92
Fillit, H. M., Hill, J. W., & Futterman, R. (2002) · PubMed · Cited by 91
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for alzheimer’s disease
Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 89
Muscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain
Müller, D., Mendla, K. D., Farber, S. A., & Nitsch, R. M. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00038-6 · Cited by 84
Jones, C. K., Eberle, E. L., Shaw, D. B., McKinzie, D. L., & Shannon, H. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075887 · Cited by 84
Beach, T. G., Honer, W. G., & Hughes, L. H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050595 · Cited by 82
Yeomans, J. S., Takeuchi, J., Baptista, M. A. S., Flynn, D. D., Lepik, K., Nóbrega, J. N., Fulton, J., & Ralph, M. R. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08861.2000 · Cited by 80
M1 Agonists for the Treatment of Alzheimer's Disease. Novel Properties and Clinical Updatea
Fisher, A., Heldman, E., Gurwitz, D., Haring, R., Karton, Y., Meshulam, H., Pittel, Z., Marciano, D., Brandeis, R., Sadot, E., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34418.x · Cited by 78
Shannon, H. E., Hart, J. C., Bymaster, F. P., Calligaro, D. O., DeLapp, N. W., Mitch, C. H., Ward, J. S., Fink‐Jensen, A., Sauerberg, P., Jeppesen, L., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34979-1 · Cited by 73
Rouse, S. T., Thomas, T. M., & Levey, A. I. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00044-1 · Cited by 71
Liao, D., Hong, C., Chen, H., Chen, Y.-E., Lee, S.-M., Chang, C.-Y., Chen, H., & Tsai, S. (2003) · Neuropsychobiology · doi:10.1159/000072880 · Cited by 56
Potential role of muscarinic receptors in schizophrenia
Bymaster, F. P., Shannon, H. E., Rasmussen, K., DeLapp, N. W., Ward, J. S., Calligaro, D. O., Mitch, C. H., Whitesitt, C. A., Ludvigsen, T. S., Sheardown, M. J., et al. (1999) · Life Sciences · doi:10.1016/s0024-3205(98)00597-9 · Cited by 54
Eckols, K., Bymaster, F. P., Mitch, C. H., Shannon, H. E., Ward, J. S., & DeLapp, N. W. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02064-p · Cited by 53
Presynaptic Muscarinic Receptors in the Central Nervous Systema
Raiteri, M., Marchi, M., & Paudice, P. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb31987.x · Cited by 53
Physostigmine and lithium response in the schizophrenias
Edelstein, P., Schultz, J. R., Hirschowitz, J., Kanter, D. R., & Garver, D. L. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.8.1078 · Cited by 53
Canet-Aviles, R., Anderton, M. J., Hooper, N. M., Turner, A. J., & Vaughan, P. F. T. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00184-5 · Cited by 52
Haring, R., Gurwitz, D., Barg, J., Pinkas‐Kramarski, R., Heldman, E., Pittel, Z., Wengier, A., Meshulam, H., Marciano, D., Karton, Y., et al. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2232 · Cited by 48
Karasawa, H., Taketo, M. M., & Matsui, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01642-x · Cited by 46
Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum
Pittel, Z., Heldman, E., Barg, J., Haring, R., & Fisher, A. (1996) · Brain Research · doi:10.1016/s0006-8993(96)01031-1 · Cited by 45
Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor
Grant, M. K. O., & El‐Fakahany, E. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090134 · Cited by 38
Ladner, C. J., & Lee, J. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7116 · Cited by 37
Rasmussen, T., Fink‐Jensen, A., Sauerberg, P., Swedberg, M. D. B., Thomsen, C., Sheardown, M. J., Jeppesen, L., Calligaro, D. O., DeLapp, N. W., Whitesitt, C. A., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00129-8 · Cited by 37
DeLapp, N. W., Wu, S., Belagaje, R. M., Johnstone, E., Little, S., Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Mitch, C. H., Whitesitt, C. A., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8235 · Cited by 33
NGF Promotes Amyloid Precursor Protein Secretion via Muscarinic Receptor Activation
Haring, R., Gurwitz, D., Barg, J., Pinkas‐Kramarski, R., Heldman, E., Pittel, Z., Danenberg, H. D., Wengier, A., Meshulam, H., Marciano, D., et al. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2092 · Cited by 33
Developing Drugs for Cognitive Impairment in Schizophrenia
Breier, A. F. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi051 · Cited by 32
Harries, M. H., Samson, N. A., Cilia, J., & Hunter, A. J. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701844 · Cited by 23
Impact on Cognition of the Use of Antipsychotics
Sharma, T. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001074 · Cited by 23
Guillem, F., Chouinard, S., Poulin, J., Godbout, R., Lalonde, P., Melun, P., Bentaleb, L. A., & Stip, É. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.02.009 · Cited by 22
Wienrich, M., Ceci, A., Ensinger, H. A., Gaida, W., Mendla, K. D., Osugi, T., Raschig, A., & Weiser, T. W. (2002) · Drug Development Research · doi:10.1002/ddr.10085 · Cited by 17
Shiozaki, K., & Iseki, E. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.002 · Cited by 12
(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00248 · Cited by 610
Muscarinic acetylcholine receptors: novel opportunities for drug development
Kruse, A. C., Kobilka, B. K., Gautam, D., Sexton, P. M., Christopoulos, A., & Wess, J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4295 · Cited by 437
Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E. T., Lazareno, S., Molloy, J. E., & Birdsall, N. J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907915107 · Cited by 383
Tropane Alkaloids: Chemistry, Pharmacology, Biosynthesis and Production
Kohnen-Johannsen, K. L., & Kayser, O. (2019) · Molecules · doi:10.3390/molecules24040796 · Cited by 351
Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes
Maeda, S., Qu, Q., Robertson, M. J., Skiniotis, G., & Kobilka, B. K. (2019) · Science · doi:10.1126/science.aaw5188 · Cited by 320
Metadata
- Authors
- Langmead, C. J., Watson, J., & Reavill, C.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 117
- Issue
- 2
- Pages
- 232-243
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2050688876
- Cited by
- 419
- References
- 100
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.